Brooklyn ImmunoTherapeutics, Inc.(NYSE Amex Equities : NTN)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|MRK||Merck & Co., Inc.||-0.06%||81.12||0.7%||$1566.02m|
|JNJ||Johnson & Johnson||0.19%||163.71||0.7%||$997.82m|
|BMY||Bristol-Myers Squibb Co.||-0.38%||57.59||1.0%||$625.23m|
|LLY||Eli Lilly & Co.||1.07%||243.75||1.1%||$585.84m|
|AVIR||Atea Pharmaceuticals, Inc.||-0.16%||12.73||0.3%||$125.28m|
|NVO||Novo Nordisk A/S||1.51%||105.99||0.1%||$89.92m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||2.27%||139.98||0.0%||$52.50m|
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.